May 7-9, Halifax Convention Centre, Halifax, Canada
Lighten the load of your staff with fully integrated and automated hemostasis and hematology solutions, allowing lab staff to focus on higher-level tasks.
Hemostasis and hematology testing often require significant hands-on time due to factors like sample preparation, interpretation, troubleshooting, and manual review, especially for complex procedures. Labs need solutions that reduce manual touchpoints, particularly when specialized skills are required. Siemens Healthineers provides specialty solutions that help labs minimize manual tasks, reduce footprint, and simplify sample management.
Unlock the power of a comprehensive suite of integrated blood testing solutions, featuring advanced optical methods, routine platelet aggregation testing, and AI-driven full-field imaging. See how our portfolio helps you tackle staffing challenges and enhance efficiency across your entire testing workflow.
See how the CN-3000 and CN-6000 Hemostasis Systems1 are transforming coagulation testing with fast, smart, and flexible solutions—all in a compact design. Learn how features like automated barcode scanning and cap piercing can help your lab reduce manual steps and improve efficiency.
Discover how the INNOVANCE Anti-Xa assay brings advanced, automated testing to your lab with fast, accurate measurement of UFH, LMWH, and direct oral anticoagulants like rivaroxaban, apixaban, and edoxaban.2 With minimal hands-on time, this chromogenic assay helps reduce human error and streamline your workflow.
The Atellica HEMA 520 and 530 Analyzers combine proven hematology testing performance in a reliable, compact bench-top instrument. Using only a small number of reagents for testing, the systems help optimize inventory management for less waste, less packaging, less toxicity.
Experience the power of Scopio X100 and X100HT—the first full-field digital cell morphology platforms with AI-driven decision support to enhance accuracy and efficiency. These cutting-edge systems automate slide scanning, helping eliminate manual reviews and saving valuable time in your lab.
Explore our scalable and customizable portfolio of automated lab and IT solutions designed to streamline workflows in labs of all sizes. See how our technologies help improve diagnostic accuracy while freeing up time from routine tasks.
Many conditions involve both hematological and hemostatic factors, making integrated testing key to faster, more efficient diagnoses. Collaboration across disciplines helps uncover clearer insights—especially in complex cases like coagulopathies or thrombocytopenia. See how Atellica Diagnostics IT brings it all together by consolidating data from multiple sources, reducing manual entry, and delivering a complete clinical picture.
Our adaptable portfolio of automated lab solutions is designed to meet diverse needs, spaces, and specialized requirements, improving workflows in labs of any size. Discover flexible, innovative options to boost standardization and enhance workflow efficiency through lab automation.
Reduce time and effort spent on low-value tasks and complex workstreams by connecting Atellica HEMA 570 and 580 Analyzers.3 Automation connectivty helps improve resource utilization, increase efficiency, and achieve consistent turnaround times.
Could lab automation from Siemens Healthineers be the solution for your lab? Automate hemostasis and hematology in a compact workcell, with single-tube transport, centrifugation, and automatic aliquoting to reduce manual steps, expand your test menu, and free up time—all in a small footprint. Learn about the wins.
Our lab automation solutions let you flexibly add analyzers and workflow modules, like pre- and post-analytics, to fit your space and needs. Together with our healthcare consulting specialists, tailor a configuration that meets your clinical and operational needs and helps you achieve more with less.
Unlock holistic insights into blood science with versatile automation—whether for single- or multidisciplinary testing. From clinical chemistry and immunoassay to hemostasis, hematology, plasma proteins, and allergy testing, streamline it all with one trusted partner and simplify your lab’s vendor management.
Our extensive range of routine and specialty hemostasis assays supports informed diagnostic and treatment decisions. We’re continually expanding with new technologies and ready-to-use solutions to simplify tasks and improve workflows. Discover how to gain deeper clinical insights in bleeding management.
Most VWD cases are congenital, but certain chronic diseases and therapies can trigger an acquired form of the disorder. Explore our resources for the latest testing guidelines and diagnostic advancements, and save time investigating best practices and current standards.
Explore our unparalleled bleeding portfolio
Streamline diagnostic testing around primary and secondary hemostasis with tests for acquired and congenital bleeding risk assessment and therapy , from one provider.
Now FDA-cleared in the U.S. as a companion diagnostic for QFITLIA (fitusiran). The liquid assay delivers consistent results across systems—supporting harmonized interpretation and reducing repeat testing to save time and reagents.
Elevate VWF diagnostics with a highly sensitive, precise, and innovative initial testing panel for von Willebrand disease. Strong precision at key decision points helps reduce repeat tests and unnecessary blood draws.
An automated platelet function analyzer for assessing inherited, acquired, or drug-induced platelet dysfunction—all from a single sample tube, minimizing handling and simplifying the process.
A breakthrough in making aggregation testing easier, more reliable, and standardized—automating platelet aggregation for five agonists with no extra pipetting or hands-on steps required.
Join our symposium to explore how lab science has driven the progress of hemophilia gene therapy from early research to real-world clinical use. We’ll dive into the lab’s role in monitoring gene therapy patients and take a look at the challenges ahead with new treatments now in development.
After several decades of basic science and pre-clinical investigation hemophilia gene therapy has entered the clinic. Several phase 3 studies have now been completed, and three hemophilia gene therapy products have received regulatory approvals. As these products begin to appear in regular clinical practice it is important to appreciate the range of laboratory studies that have contributed to the advancement of this treatment paradigm. This presentation will discuss details of laboratory studies employed in the development of gene therapy programs and the requirements of laboratory monitoring in patients who have undergone gene therapy treatment. In addition to “routine” substitution gene therapy, the presentation will also highlight challenges for the laboratory in the evaluation of other novel hemophilia treatments that are in early phases of development.
Date: May 7-9
Location: Halifax, Nova Scotia, Canada
Venue: Halifax Convention Centre
(maps)
Are you interested?
Share
Do you find this page interesting? Share the information with peers.